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Abstract 
Background and Objective 
Dried blood spot (DBS) sampling has gained wide interest in bioanalysis during the last decade. 
Also in pharmacokinetic and phenotyping studies, DBS-based sampling has already been 
successfully applied. However, all available phenotyping studies used small data sets and did not 
include a systematic evaluation of DBS-specific parameters. The latter is important since several 
of these factors still challenge the breakthrough of DBS in routine practice. In this study, caffeine 
and paraxanthine are determined in capillary DBS, venous DBS, whole blood and plasma for 
CYP1A2 phenotyping (CYP; cytochrome P450). The aim of this study was to explore the 
usefulness of DBS as a tool for CYP1A2 phenotyping. 
Methods 
A CYP1A2 phenotyping study was conducted in seventy-three healthy volunteers, who received 
a 150 mg oral dose of caffeine. Six hours post-administration, caffeine and paraxanthine 
concentrations and paraxanthine:caffeine molar concentration ratios, i.e. the actual CYP1A2 
phenotyping indices, were determined in capillary DBS (obtained by non-volumetric application, 
direct from the fingertip), venous DBS, whole blood and plasma. Furthermore, the impact of 
DBS-specific parameters, including hematocrit, volume spotted and punch location, was 
evaluated. 
Results  
Concentrations of caffeine and paraxanthine in capillary DBS were on average 12.7 respectively 
13.8 % lower than those in venous DBS and 31.5 respectively 33.1 % lower than those in plasma. 
While these differences were statistically significant (p < 0.001), no significant difference was 
observed between the paraxanthine:caffeine molar ratios in the distinct evaluated matrices (p ≥ 
0.053). This ratio also alleviated the impact of hematocrit and volume spotted. 
Conclusions 
Using the largest DBS-based phenotyping study to date, we have demonstrated that CYP1A2 
phenotyping in capillary DBS is a valid and convenient alternative for the classical plasma-based 
approach. Additionally, we have provided an objective basis as to why DBS are an ideal tool for 
CYP1A2 phenotyping. 
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Key points 
 A CYP1A2 phenotyping study, conducted in seventy-three healthy volunteers, 
demonstrated equivalence between phenotyping indices, i.e. paraxanthine:caffeine molar 
concentration ratios, in capillary DBS (obtained by non-volumetric application, direct 
from the fingertip) and venous plasma. 
 While capillary DBS concentrations of caffeine and paraxanthine differed significantly 
from those in venous blood and plasma and were impacted by hematocrit and blood 
volume spotted, the paraxanthine:caffeine molar ratio essentially remained unaffected. 
 Capillary DBS-based CYP1A2 phenotyping proved to be a valid and convenient 
alternative for the classical plasma-based approach. 
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1 Introduction 
During the last decade, dried blood spot (DBS) sampling has become a widely used 
microsampling technique in bioanalysis, owing to the development of more sensitive analytical 
techniques and various benefits offered by the technique itself [1-5]. Among the advantages are 
minimal invasiveness, easy sample collection and improved compound stability. This allows the 
collection of representative samples by an informed patient himself in his home-environment, 
followed by convenient and cost-effective transfer, e.g. via regular mail, to the analytical 
laboratory [6]. 
However, despite the many advantages, several issues concerning DBS analytics and the 
potential to fully replace venous sampling still remain. First of all, being a capillary sampling 
technique, the correlation between venous and capillary concentrations is one of the key points 
that needs to be evaluated when setting up DBS-based methods [7, 8]. Furthermore, adequate 
interpretation of DBS results requires comparison with plasma or serum concentrations, as 
clinical reference intervals are commonly based on the latter [9]. Finally, potential bias 
introduced by the spotting technique itself must be excluded, for example by comparing 
concentrations measured in venous whole blood samples with concentrations in venous DBS. 
From an analytical perspective, the (combined) influence of hematocrit (Hct), blood volume 
spotted and punch localization on a DBS result are important challenges to be addressed during 
method development and validation [2, 3, 10-12]. The degree of bias caused by these parameters 
needs to be evaluated on a case-by-case basis since it may be influenced by several factors, such 
as compound characteristics, filter paper type or extraction conditions.  
CYP1A2 (CYP; cytochrome P450), an enzyme whose activity is subject to large inter-individual 
variability, is involved in the metabolism of several therapeutic drugs, including the 
antipsychotics clozapine and olanzapine. Consequently, the response to these drugs will be 
influenced by CYP1A2 status [13].
 
Since CYP1A2 activity is determined by genetic, 
environmental and nongenetic endogenous factors [14-16], phenotyping with a selective substrate 
rather than genotyping is commonly used to assess enzyme activity. Caffeine is widely accepted 
as model substrate of CYP1A2, owing to its safety profile and since the N3-demethylation to 
paraxanthine is almost uniquely controlled by CYP1A2. Measuring caffeine clearance via a full 
concentration-time profile is considered as the gold standard for CYP1A2 activity determination 
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[17]. However, as this approach is inconvenient, the paraxanthine:caffeine ratio in plasma, 
measured 5-7h after controlled caffeine administration (100–200 mg), is a generally accepted 
metric for this purpose [18, 19].
  
A proof-of-principle of DBS-based phenotyping has already been shown for CYP3A4 [20] and 
CYP2C9 [21]. Very recently, two groups reported on the use of a cocktail approach to 
simultaneously phenotype multiple enzymes, including CYP1A2, in DBS [22, 23]. However, all 
these studies were conducted in a very limited number of volunteers (n ≤ 16), hampering 
thorough statistical evaluation. In all cases, except for the study by Donzelli et al. [23], blood 
spots were volumetrically applied to the filter paper in a controlled environment [20-22]. 
Moreover, no systematic investigation of parameters potentially influencing the phenotyping 
index has been undertaken, yet. Therefore, the main objective of this study was to explore the 
usefulness of DBS as a matrix for CYP1A2 phenotyping.  
2 Methods 
2.1 CYP1A2 phenotyping study 
A CYP1A2 phenotyping study was conducted in healthy volunteers. The study was approved by 
the Ethics Committee of Ghent University Hospital (B670201111655). Sample size was selected 
based on the following factors: i) feasibility of the study; ii) the possibility to conduct statistical 
analyses, such as Bland-Altman comparison and Passing-Bablok regression analysis; iii) 
estimation of the required sample size to investigate differences between caffeine and 
paraxanthine concentrations and paraxanthine:caffeine ratios at a significance level of 0.05 and 
power of 90%. The latter calculation was based on data of a preliminary CYP1A2 phenotyping 
study in dried blood spots, whole blood and plasma [24]. Relevant differences between caffeine 
and paraxanthine concentrations in the different matrices were chosen at 0.08 and 0.04 µg/mL 
respectively, being 10% of the lowest concentrations measured in the preliminary study. For the 
paraxanthine:caffeine ratio, a difference of 0.05 was considered relevant. The highest required 
sample size for the intended comparisons between the different matrices resulting from this 
calculation was 59. Based on these data, a sample size of 73 individuals was considered adequate 
for the planned study. Written informed consent was obtained from each subject. Participants 
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were asked to cease caffeine ingestion for 36 hours prior to intake of a capsule containing 150 mg 
caffeine. Capillary DBS were collected 5 minutes before and 6 hours after administration. At the 
6-hour time point (± 5 minutes), venous whole blood samples were collected as well. Plasma 
samples and venous DBS were prepared within 1 hour after blood sampling. Concentrations of 
caffeine and paraxanthine (and the corresponding paraxanthine:caffeine molar concentration 
ratios) were determined in capillary DBS, venous DBS, whole blood and plasma. 
2.2 Sample collection 
Capillary DBS were obtained by direct application of a drop of blood from the fingertip onto 
Whatman 903 filter paper cards (WHA10334885, GE Healthcare, Dassel, Germany). Instructions 
on good sampling practices were given to all participants by means of a hands-on demonstration 
and an illustrated flyer. Following disinfection of the fingertip, finger pricks were made with an 
automated lancet (VAC366594, Becton Dickinson, Franklin Lakes, NJ, USA). The first drop of 
blood was wiped off and the following drops, at least four for every participant, were collected on 
the DBS cards, thereby ensuring that a single drop was used for every spot and avoiding direct 
contact between filter paper and fingertip. DBS of which both sides of the filter paper were 
colored were analyzed. Venous blood, collected in ethylenediaminetetraacetic acid (EDTA) tubes 
(Venosafe
®
 4 mL VF-054SDK, Terumo, Leuven, Belgium), was used for preparing venous DBS 
by spotting 25 µL of blood onto Whatman 903 filter paper using a calibrated pipette and for 
preparing plasma. Liquid samples were stored at -20 °C, DBS were dried for at least 2 hours and 
stored at ambient temperature in zip-closure plastic bags, containing two 5-g packets of desiccant 
(Minipax
® 
absorbent packets, Sigma-Aldrich, Diegem, Belgium), until analysis. For evaluating 
DBS-specific parameters, venous whole blood from a caffeine abstinent healthy, male volunteer 
was collected in EDTA tubes (Venosafe
®
 9 mL VF-109SDK, Terumo). 
2.3 Chemicals 
Caffeine, paraxanthine, theophylline, theobromine, the internal standards (IS) caffeine-
13
C3 and 
paraxanthine-
13
C4-
15
N3, and formic acid were purchased from Sigma-Aldrich. Methanol and 
acetonitrile, both of LC-MS quality, were from Biosolve (Valkenswaard, The Netherlands). A 
Synergy
® 
Water Purification System (Merck Millipore, Overijse, Belgium) provided ultrapure 
water.  
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2.4 Sample preparation and analysis 
For all DBS analyses, 3-mm discs were punched from the center of a DBS using a Harris micro-
punch and cutting mat (Sigma-Aldrich). As capillary DBS were generated in a non-volumetric 
way, resulting in spots with varying sizes, we opted to punch 3-mm discs. These were extracted 
with 70 µL of a methanol/water (80/20, v/v) mixture, containing 0.01% formic acid and the 
internal standards. For plasma and whole blood, we used a simple protein precipitation 
procedure, starting from 50 L sample, to which 10 µL of IS solution was added, prior to the 
addition of 100 µL methanol, containing 0.01% formic acid. After centrifugation, supernatants 
were diluted with water, containing 0.01% formic acid, until starting conditions were reached. 
Full details on sample preparation procedures are described elsewhere [24]. 
All samples were analyzed on a Waters Acquity UPLC
®
 system (Waters, Milford, MA, USA) 
coupled to an AB SCIEX API 4000
™
 triple quadrupole mass spectrometer (AB SCIEX, 
Framingham, MA, USA), as described elsewhere [24]. Quantitative analyses were performed for 
caffeine and paraxanthine. Theophylline and theobromine, being metabolites of caffeine with the 
same molecular mass as paraxanthine, were qualitatively monitored in every analytical run to 
ensure selectivity. The methods used were fully validated based on U.S. Food and Drug 
Administration (FDA) and European Medicines Agency (EMA) guidelines for bioanalytical 
method validation [25, 26]. No interferences or carry-over were observed for any of the matrices. 
Linear calibration curves were obtained for both caffeine and paraxanthine (respectively 0.05-
10.0 and 0.025-5.0 µg/ml). Intrabatch precision (%CV; coefficient of variation) was below 
11.40% (DBS), 5.44 % (whole blood) and 5.47% (plasma), while interbatch precision (%CV) 
was below 14.79% (DBS), 16.12% (whole blood) and 10.39% (plasma). Accuracy (%bias) was 
below 11.66% (DBS), 8.49% (whole blood) and 4.10% (plasma). All matrix effect and recovery 
data approximated 100% and were reproducible. DBS were stable for 324 days at room 
temperature and for 4 days at 50°C. Whole blood and plasma samples were stable for 172 days at 
-20°C.  
2.4.1 Impact of DBS-specific parameters on CYP1A2 phenotyping index 
To evaluate the effect of varying hematocrit (Hct) on the concentration of caffeine and 
paraxanthine, we prepared blood samples with Hct values of 0.20, 0.25, 0.30, 0.43, 0.54 and 0.60 
as described before [27]. These were used to prepare low and high quality control samples (QCs) 
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(n=6; respectively 0.12 and 8.0 g/mL for caffeine and 0.06 and 4.0 g/mL for paraxanthine), 
from which 25-L DBS were prepared. The influence of blood volume spotted and the impact of 
punch localization were investigated by preparing low and high QCs in blood with Hct at low 
(0.36  0.007), intermediate (0.43  0.006) and high (0.50  0.008) Hct. These Hct values were 
chosen based upon the reference ranges for women and men, which lie at approximately 0.36 – 
0.44 and 0.41 – 0.50, respectively [11]. To evaluate the volume effect, different volumes of blood 
(7.5, 25 and 50 µL) were spotted onto the filter paper (n=6). For the effect of both Hct and 
volume, the results obtained for 25 µL DBS with a Hct of 0.43 were taken as a reference. The 
impact of punch localization was evaluated by comparing concentrations measured in central 
versus peripheral punches (n=6) using an independent samples t-test (α=0.05).  
2.5  Data analysis 
Peak areas were determined using AB SCIEX Analyst 1.5.2 software. Microsoft Excel 2010 and 
IBM SPSS Statistics 20 were used for statistical evaluation of the data. Bland-Altman plots and 
Passing-Bablok regression analyses were generated using MedCalc Version 12.7.5. 
3 Results 
3.1 CYP1A2 phenotyping study 
Seventy-three healthy volunteers (age 21 – 48 years) participated in the study, including 50 
women and 4 smokers. All participants received a 150 mg oral dose of caffeine. Caffeine and 
paraxanthine concentrations were determined in capillary DBS obtained 5 minutes before 
administration and in capillary DBS, venous DBS, whole blood and plasma obtained 6 hours 
post-administration. Table 1 shows the median concentrations, along with the observed ranges at 
the 6-hour time point. For 12 volunteers, whole blood samples were not available. Since Perera et 
al. found that paraxanthine:caffeine ratios were not affected by pre-dose concentrations, whether 
or not a 24-hour abstinence period was applied [28], the pre-dose concentrations were not taken 
into account in this study. Bland-Altman comparisons were used to evaluate the data obtained for 
the different matrices. The mean differences and the limits of agreement (LoAs) are listed in 
Table 2. Percentage plots were constructed since standard deviations increased with measured 
concentrations or concentration ratios for most comparisons [29].
 
Venous whole blood 
concentrations of caffeine and paraxanthine were on average respectively 15.2 and 16.6% lower 
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than concentrations measured in corresponding plasma samples (p < 0.001). Surprisingly, also a 
difference between capillary and venous DBS was observed: concentrations of caffeine and 
paraxanthine in capillary DBS were on average respectively 12.7 and 13.8% lower than in venous 
DBS (p < 0.001). There was no significant difference between concentrations in venous DBS and 
venous whole blood samples (p ≥ 0.089), demonstrating the validity of the DBS approach: the 
entire process of spotting, drying and storing of the samples had no influence on the analytical 
result. As a result, concentrations in capillary DBS were significantly (p < 0.001) and 
considerably lower than concentrations in venous plasma samples (on average -31.5 and -33.1% 
for caffeine and paraxanthine, respectively). However, the use of paraxanthine:caffeine molar 
concentration ratios alleviated both the blood-plasma difference and the capillary-venous 
difference: mean differences between the different matrices were only -1.6 to 0.6% (Table 2). In 
addition, paired samples t-tests showed no significant differences between ratios measured in the 
different matrices (p ≥ 0.053). The differences between measured concentrations in capillary 
DBS and plasma on the one hand and the equivalence between the phenotyping indices obtained 
from these matrices on the other hand can readily be deduced from Figure 1, depicting the 
Passing-Bablok regression analyses of caffeine concentrations (Figure 1a), paraxanthine 
concentrations (Figure 1b) and paraxanthine:caffeine molar concentration ratios (Figure 1c), as 
well as the Bland-Altman comparison of these ratios (Figure 1d) in capillary DBS versus those in 
the reference matrix for CYP1A2 phenotyping, i.e. venous plasma. Bland-Altman plots and 
Passing-Bablok regression analyses for all comparisons are shown in Supplementary Figures S1-
S6. 
3.2 DBS-specific parameters 
To evaluate whether -besides capillary-venous differences- other DBS-specific parameters may 
have an impact on caffeine and paraxanthine quantitation, we varied the Hct, volume spotted and 
site of punching. Although we and others [20-24] demonstrated that DBS can be used for 
phenotyping CYP enzymes, no report has evaluated the impact of variation of these parameters 
on the phenotyping index. First, we did not observe significant differences between caffeine and 
paraxanthine concentrations measured in discs punched out peripherally versus centrally, 
irrespective of the Hct (Supplementary Figure S7). Next, we measured caffeine and paraxanthine 
concentrations (low and high QCs) in DBS, prepared from blood with varying Hct. Figure 2a 
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depicts the % of the normalized sample with Hct 0.43, being the Hct of the calibrators, for all 
tested Hct levels. A “Hct effect”, i.e. increasingly deviating measured concentrations with 
increasingly deviating Hct levels, was observed for both compounds. While in the 0.30 - 0.60 Hct 
range, measured concentrations were overall within ± 15% of the concentration of the normalized 
sample, deviations overall exceeded 15% at the lowest Hct levels (0.20 and 0.25). Importantly, no 
suchlike influence of the Hct on the paraxanthine:caffeine molar ratio (i.e. the actual phenotyping 
index) was observed (Figure 2b), indicating that both compounds are subject to a similar Hct 
effect. 
The influence of the blood volume spotted was evaluated by analyzing DBS with three different 
blood volumes and Hct levels, taking a 25 µl DBS with Hct 0.43 as the reference. For both 
caffeine and paraxanthine, we observed a trend of increasing concentrations with increased blood 
volumes, although differences from the normalized sample were overall within ± 15% (Figure 
2c). Similar to the Hct effect, the paraxanthine:caffeine molar ratio was unaffected by the blood 
volume (Figure 2d). 
4. Discussion 
Several approaches have been proposed as convenient alternatives for classical plasma-based 
phenotyping. While for CYP1A2, Perera et al. readily demonstrated the utility of oral fluid for 
phenotyping [28], we investigated here in-depth the potential of DBS for this purpose. In this 
study, which is the largest published DBS-based phenotyping study to date, caffeine and its main 
metabolite paraxanthine were determined in capillary DBS, venous DBS, whole blood and 
plasma in the context of CYP1A2 phenotyping. Although a proof-of-principle of DBS-based 
CYP phenotyping is already available [20-24], all published studies had small data sets (n  16) 
and did not include a systematic evaluation of DBS-specific parameters. Moreover, with a single 
exception [23], all studies started from volumetrically applied DBS, an approach that is difficult 
to sustain when envisaging patient self-sampling at home. In this study, by taking CYP1A2 as an 
example, the usefulness of a DBS-based phenotyping approach was demonstrated in 73 
volunteers using spots prepared by non-experienced individuals in a non-volumetric way. By 
thoroughly investigating several known challenges associated with DBS analysis, we provide a 
better insight in the factors underlying the trustworthiness of DBS for phenotyping purposes.  
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First of all, significant differences were found between blood and plasma concentrations and 
between capillary and venous concentrations. As caffeine and most probably also paraxanthine 
(given their structural similarity) exhibit low binding to plasma proteins and freely enter blood 
cells without binding to cellular proteins, plasma and blood concentrations should be very 
similar. Taking into account the fraction of solid constituents in blood, the blood concentration 
could be expected to lie approximately 15% lower than the plasma concentration [9, 30]. The 
observed differences (15.2 and 16.6% for caffeine and paraxanthine, respectively) are in line with 
this expectation. Differences between capillary and venous concentrations have been found for 
several other small molecules (e.g. piperaquine, paracetamol) [7, 8]. However, lower capillary 
concentrations of caffeine and paraxanthine compared to venous concentrations, have, to the best 
of our knowledge, not been described before. Although we cannot fully exclude that 
anticoagulated blood spotted onto filter paper might exhibit a somewhat different behavior than 
blood without anticoagulant which is directly applied to the filter paper, we are not aware of 
evidence supporting this hypothesis. Instead, we consider it more likely that the observed 
differences between venous and capillary concentrations are caused by as yet incompletely 
understood physiological factors [31]. 
In addition to the factors described above, we also evaluated the influence of Hct, blood volume 
spotted and punch localization. Hct and blood volume had a considerable impact on the 
concentrations of caffeine and paraxanthine, similar to that described for several other small 
molecules [32-35]. The range in which the impact of Hct was evaluated, 0.20 – 0.60, was 
considered to be relevant and sufficient, as it covers approximately 99.5% of a hospital 
population (including both ‘normal’ and ‘critically ill’ patients) [10]. The 7.5 – 50 µL volume 
range was chosen to represent typical spot sizes resulting from a single drop of blood. Taken the 
above into account, it can be concluded that, apart from the plasma-blood and the capillary blood-
venous blood difference, also the impact of Hct and volume spotted complicate the interpretation 
of DBS results. However, we demonstrated that the mean differences between ratios in the 
different matrices were very limited (-1.6 to 0.6%) and that the paraxanthine:caffeine molar ratio 
was unaffected by both Hct and blood volume. The use of metabolite:substrate ratios may 
therefore offer a strategy to by-pass the impact of these DBS-related issues, demonstrating the 
usefulness of DBS-based phenotyping approaches. 
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Further evidence for the suitability of capillary DBS as a valid alternative for plasma, here 
considered the reference matrix, in the context of CYP1A2 phenotyping is given by the 
following: i) the 95% confidence interval of the average difference between 
paraxanthine:caffeine ratios in capillary DBS and plasma, obtained by Bland-Altman 
comparison, contained 0 (Figure 1d), indicating the absence of a consistent bias; ii) Passing-
Bablok regression analysis yielded a good correlation between phenotyping indices from 
capillary DBS and plasma. As the 95% confidence intervals of the intercept and the slope contain 
0 and 1, respectively (Figure 1c), there were no systematic and proportional differences between 
the two methods; iii) there was no significant difference between ratios in both matrices, as 
determined by a paired samples t-test; iv) although no general cut-off points concerning the 
CYP1A2 phenotype (poor versus rapid metabolizer) are available, we found that the 10% lowest 
and highest ratios measured in plasma and capillary DBS corresponded to the same subjects. In 
this study, the phenotyping index in plasma ranged from 0.090-0.95, which is in line with 
previous reports [36, 37].  
4 Conclusion 
In the largest published DBS-based phenotyping study to date, we demonstrated that quantitation 
of caffeine and paraxanthine in non-volumetrically applied capillary DBS is not only impacted by 
Hct and volume spotted, but also significantly differs from venous blood and plasma-based 
quantitation. However, as the use of the paraxanthine:caffeine molar ratio, i.e. the actual 
CYP1A2 phenotyping index, alleviates all these issues, we not only demonstrated here that 
capillary DBS-based CYP1A2 phenotyping is a valid and convenient alternative for the classical 
plasma-based approach, but, importantly, we also provided an objective basis as to why DBS are 
an ideal tool for CYP1A2 phenotyping. It needs to be evaluated whether these findings can be 
generalized for other CYP isoforms, using other CYP substrates.  
13 
 
Acknowledgements 
The authors wish to thank all volunteers who participated in the phenotyping study. 
 
Conflicts of Interest 
The authors have no conflict of interest to declare. This study was financed by the Laboratory of 
Toxicology, Ghent University, Belgium. The authors received no additional funding directly 
related to the content of this study. 
 
References 
 
1. Demirev PA. Dried blood spots: analysis and applications. Anal Chem. 2013;85(2):779-
89. 
 
2. Edelbroek PM, van der Heijden J, Stolk LM. Dried blood spot methods in therapeutic 
drug monitoring: methods, assays, and pitfalls. Ther Drug Monit. 2009;31(3):327-36. 
 
3. Li W, Tse FL. Dried blood spot sampling in combination with LC-MS/MS for 
quantitative analysis of small molecules. Biomed Chromatogr. 2010;24(1):49-65. 
 
4. Meesters RJ, Hooff GP. State-of-the-art dried blood spot analysis: an overview of recent 
advances and future trends. Bioanalysis. 2013;5(17):2187-208. 
 
5. Stove CP, Ingels AS, De Kesel PM, Lambert WE. Dried blood spots in toxicology: from 
the cradle to the grave? Crit Rev Toxicol. 2012;42(3):230-43. 
 
6. Ingels AS, Hertegonne K, Lambert WE, Stove CP. Feasibility of following up gamma-
hydroxybutyric acid concentrations in sodium oxybate (Xyrem
®
)-treated narcoleptic 
patients using dried blood spot sampling at home:  an exploratory study. CNS Drugs. 
2013;27(3):233-7.  
 
7. Ashley EA, Stepniewska K, Lindegardh N, Annerberg A, Tarning J, McGready R et al. 
Comparison of plasma, venous and capillary blood levels of piperaquine in patients with 
uncomplicated falciparum malaria. Eur J Clin Pharmacol. 2010;66(7):705-12. 
 
8. Mohammed BS, Cameron GA, Cameron L, Hawksworth GH, Helms PJ, Mclay JS. Can 
finger-prick sampling replace venous sampling to determine the pharmacokinetic profile 
of oral paracetamol? Brit J Clin Pharmacol. 2010;70(1):52-6. 
14 
 
 
9. Rowland M, Emmons GT. Use of Dried blood spots in drug development: 
pharmacokinetic considerations. AAPS Journal. 2010;12(3):290-3. 
 
10. De Kesel PM, Sadones N, Capiau S, Lambert WE, Stove CP. Hemato-critical issues in 
quantitative analysis of dried blood spots: challenges and solutions. Bioanalysis. 
2013;5(16):2023-41. 
 
11. Denniff P, Spooner N. The effect of hematocrit on assay bias when using DBS samples 
for the quantitative bioanalysis of drugs. Bioanalysis. 2010;2(8):1385-95. 
 
12. O'Mara M, Hudson-Curtis B, Olson K, Yueh Y, Dunn J, Spooner N. The effect of 
hematocrit and punch location on assay bias during quantitative bioanalysis of dried 
blood spot samples. Bioanalysis. 2011;3(20):2335-47. 
 
13. Arranz MJ, de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a 
review of last decade of research. Mol Psychiatry. 2007;12(8):707-47. 
 
14. Magnusson MO, Dahl ML, Cederberg J, Karlsson MO, Sandstrom R. Pharmacodynamics 
of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by 
probe substrates midazolam, caffeine, and digoxin. Clin Pharmacol Ther. 2008;84(1):52-
62. 
 
15. Tantcheva-Poor I, Zaigler M, Rietbrock S, Fuhr U. Estimation of cytochrome P-450 
CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. 
Pharmacogenetics. 1999;9(2):131-44.  
 
16. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of 
gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 
2013;138(1):103-41. 
 
17. Kalow W, Tang BK. The use of caffeine for enzyme assays - a critical appraisal. Clin 
Pharmacol Ther. 1993;53(5):503-14.  
 
18. Fuhr U, Jetter A, Kirchheiner J. Appropriate phenotyping procedures for drug 
metabolizing enzymes and transporters in humans and their simultaneous use in the 
"cocktail" approach. Clin Pharmacol Ther. 2007;81(2):270-83. 
 
19. Perera V, Gross AS, McLachlan AJ. Measurement of CYP1A2 activity: a focus on 
caffeine as a probe. Curr Drug Metab. 2012;13(5):667-78.  
 
20. de Boer T, Wieling J, Meulman E, Reuvers M, Renkema G, den Daas I et al. Application 
of dried blood spot sampling combined with LC-MS/MS for genotyping and phenotyping 
of CYP450 enzymes in healthy volunteers. Biomed Chromatogr. 2011;25(10):1112-23. 
 
15 
 
21. Daali Y, Samer C, Deglon J, Thomas A, Chabert J, Rebsamen M et al. Oral flurbiprofen 
metabolic ratio assessment using a single-point dried blood spot. Clin Pharmacol Ther. 
2012;91(3):489-96. 
 
22. Bosilkovska M, Deglon J, Samer C, Walder B, Desmeules J, Staub C et al. Simultaneous 
LC-MS/MS quantification of P-glycoprotein and cytochrome P450 probe substrates and 
their metabolites in DBS and plasma. Bioanalysis. 2014;6(2):151-64. 
 
23. Donzelli M, Derungs A, Serratore MG, Noppen C, Nezic L, Krahenbuhl S et al. The 
Basel cocktail for simultaneous phenotyping of human cytochrome P450 isoforms in 
plasma, saliva and dried blood spots. Clin Pharmacokinet. 2014;53(3):271-82. 
 
24. De Kesel PM, Lambert WE, Stove CP. CYP1A2 phenotyping in dried blood spots and 
microvolumes of whole blood and plasma. Bioanalysis. 2014;accepted. 
 
25. European Medicines Agency. Guideline on bioanalytical method validation.  
 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/
WC500150010.pdf (Accessed March 2014). 
 
26. U.S. Department of Health and Human Services. Food and Drug Administration. Center 
for Drug Evaluation and Research. Center for Veterinary Medicine. Draft Guidance for 
Industry. Bioanalytical Method Validation.  
 
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidance
s/ucm368107.pdf (Accessed March 2014). 
 
27. Capiau S, Stove VV, Lambert WE, Stove CP. Prediction of the hematocrit of dried blood 
spots via potassium measurement on a routine clinical chemistry analyzer. Anal Chem. 
2013;85(1):404-10. 
 
28. Perera V, Gross AS, Xu H, McLachlan AJ. Pharmacokinetics of caffeine in plasma and 
saliva, and the influence of caffeine abstinence on CYP1A2 metrics. J Pharm Pharmacol. 
2011;63(9):1161-8. 
 
29. Dewitte K, Fierens C, Stockl D, Thienpont LM. Application of the Bland-Altman plot for 
interpretation of method-comparison studies: a critical investigation of its practice. Clin 
Chem. 2002;48(5):799-801. 
 
30. Rainey PM. Relation between serum and whole-blood ethanol concentrations. Clin Chem. 
1993;39(11):2288-92.  
 
31. Chiou WL. The phenomenon and rationale of marked dependence of drug concentration 
on blood sampling site. Implications in pharmacokinetics, pharmacodynamics, toxicology 
and therapeutics (Part II). Clin Pharmacokinet. 1989;17(4):275-90. 
 
16 
 
32. Holub M, Tuschl K, Ratschmann R, Strnadova KA, Muhl A, Heinze G et al. Influence of 
hematocrit and localisation of punch in dried blood spots on levels of amino acids and 
acylcarnitines measured by tandem mass spectrometry. Clin Chim Acta. 2006;373(1-
2):27-31. 
 
33. Ingels AS, De Paepe P, Anseeuw K, Van Sassenbroeck D, Neels H, Lambert W et al. 
Dried blood spot punches for confirmation of suspected gamma-hydroxybutyric acid 
intoxications: validation of an optimized GC-MS procedure. Bioanalysis. 
2011;3(20):2271-81. 
 
34. Mess JN, Taillon MP, Cote C, Garofolo F. Dried blood spot on-card derivatization: an 
alternative form of sample handling to overcome the instability of thiorphan in biological 
matrix. Biomed Chromatogr. 2012;26(12):1617-24. 
 
35. Vu DH, Koster RA, Alffenaar JW, Brouwers JR, Uges DR. Determination of 
moxifloxacin in dried blood spots using LC-MS/MS and the impact of the hematocrit and 
blood volume. J Chromatogr B: Analyt Technol Biomed Life Sci. 2011;879(15-16):1063-
70. 
 
36. Dobrinas M, Cornuz J, Oneda B, Kohler Serra M, Puhl M, Eap CB. Impact of smoking, 
smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility. 
Clin Pharmacol Ther. 2011;90(1):117-25. 
 
37. Han XM, Ou-Yang DS, Lu PX, Jiang CH, Shu Y, Chen XP et al. Plasma caffeine 
metabolite ratio (17X/137X) in vivo associated with G-2964A and C734A 
polymorphisms of human CYP1A2. Pharmacogenetics. 2001;11(5):429-35. 
 
 
 
 
 
 
 
 
 
 
 
 
17 
 
Table 1 Caffeine and paraxanthine concentrations in capillary dried blood spots, venous dried 
blood spots, whole blood and plasma (n=73, n=61 for venous whole blood) obtained 6 hours after 
administration of a 150  mg oral caffeine dose. The median concentrations together with the 
observed concentration ranges are listed. 
Matrix Caffeine concentration Paraxanthine concentration 
 µg/mL nmol/mL µg/mL nmol/mL 
Capillary DBS 
Median 
Range 
 
1.80 
0.73 – 3.92 
 
9.28 
3.76 – 20.20 
 
0.64 
0.27 – 0.96 
 
3.53 
1.51 – 5.34 
     
Venous DBS 
Median 
Range 
 
2.13 
0.90 – 3.95 
 
10.99 
4.62 – 20.32 
 
0.73 
0.28 – 1.10 
 
4.03 
1.53 – 6.09 
     
Venous blood 
Median 
Range 
 
2.15 
0.78 – 4.17 
 
11.06 
4.00 – 21.49 
 
0.73 
0.31 – 1.06 
 
4.05 
1.70 – 5.86 
     
Venous plasma 
Median 
Range 
 
2.56 
1.00 – 4.58 
 
13.17 
5.15 – 23.56 
 
0.90 
0.36 – 1.30 
 
5.00 
2.00 – 7.24 
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Table 2 Bland-Altman comparisons of concentrations of caffeine and paraxanthine and 
paraxanthine:caffeine molar concentration ratios measured in venous whole blood, plasma and 
dried blood spots and capillary dried blood spots (n=73, n=61 for comparisons with venous 
whole blood). The mean differences together with the limits of agreement (LoAs) are listed, with 
the respective 95% confidence intervals (values between square brackets). 
Comparators Statistics 
Caffeine 
concentration 
Paraxanthine 
concentration 
Paraxanthine:caffeine 
molar ratio 
Venous blood – 
venous plasma 
Upper LoA (%) -3.8 [-6.4 – -1.3] -6.7 [-8.9 – -4.4] 9.4 [6.9 – 11.8] 
Mean difference (%) -15.2 [-16.7 – -13.7] -16.6 [-17.8 –-15.3] -1.4 [-2.8 – 0.012] 
Lower LoA (%) -26.5 [-29.1 – -24.0] -26.5 [-28.7 – -24.2] -12.1 [-14.6 – -9.7] 
 
  
  
Venous DBS – 
venous blood 
Upper LoA (%) 17.0 [12.8 – 21.3] 7.4 [5.5 – 9.3] 16.9 [13.2 – 20.5] 
Mean difference (%) -1.9 [-4.3 – 0.62] -1.3 [-2.4 – -0.1] 0.6 [-1.5 – 2.7] 
Lower LoA (%) -20.7 [-25.0 – -16.5] -9.9 [-11.8 – -8.0] -15.7 [-19.3 – -12.0] 
 
  
  
Capillary DBS – 
venous DBS 
Upper LoA (%) 18.2 [11.9 – 24.5] 16.5 [10.3 – 22.7] 19.2 [15.1 – 23.3] 
Mean difference (%) -12.7 [-16.4 – -9.0] -13.8 [-17.4 – -10.2] -1.1 [-3.5 – 1.3] 
Lower LoA (%) -43.6 [-49.9 – -37.3] -44.1 [-50.3 – -37.9] -21.4 [-25.5 – -17.2] 
 
  
  
Capillary DBS – 
venous plasma 
Upper LoA (%) -9.8 [-14.2 – -5.4] -11.3 [-15.7 – -6.8] 13.0 [10.0 – 16.0] 
Mean difference (%) -31.5 [-34.1 – -28.9] -33.1 [-35.7 – -30.5] -1.6 [-3.3 – 0.1] 
Lower LoA (%) -53.2 [-57.7 – -48.8] -54.9 [-59.3 – -50.4] -16.2 [-19.2 – -13.2] 
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Figure 1 Passing-Bablok regression analysis of caffeine concentrations (a), paraxanthine 
concentrations (b), paraxanthine:caffeine molar concentration ratios (c) and Bland-Altman 
comparison of the paraxanthine:caffeine molar concentration ratios (d) in capillary dried blood 
spots and venous plasma samples (n=73). For the Passing-Bablok regression analyses, 95% 
confidence intervals of slope and intercept are shown between square brackets. In the Bland-
Altman plot, the mean difference and the limits of agreement (LoA) are displayed, together with 
the 95% confidence limits (broken lines). 
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Figure 2 Influence of hematocrit on caffeine and paraxanthine concentrations (a) and 
paraxanthine:caffeine molar ratios (b). Influence of blood volume spotted on caffeine and 
paraxanthine concentrations (c) and paraxanthine:caffeine molar ratios (d). Data are presented as 
percentage of normalized samples with Hct 0.43 and blood volume of 25 µL (n=6). Dotted lines 
indicate the ± 15% deviation limits. 
 
